Literature DB >> 6143625

Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.

H O Ventura, F H Messerli, E D Frohlich, I Kobrin, W Oigman, F G Dunn, R M Carey.   

Abstract

Systemic, splanchnic, and renal hemodynamics, intravascular volume, and reflexive and endocrine changes were measured before and after a single dose of fenoldopam, a novel antihypertensive agent that acts through stimulation of specific dopamine receptors. A 13% reduction in mean arterial pressure was mediated by a fall in total peripheral resistance association with an increase in cardiac index, heart rate, stroke volume, left ventricular ejection rate, and circumferential fiber shortening. Renal blood flow increased, thereby reducing the renal vascular resistance by more than 40%. In contrast, splanchnic hemodynamics failed to change. Likewise, there were no changes in intravascular volume, plasma renin activity, or norepinephrine, serum aldosterone, or prolactin levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143625     DOI: 10.1161/01.cir.69.6.1142

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist.

Authors:  S S Ng; C C Pang
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Lithium and the renal response to gludopa, fenoldopam and dopamine.

Authors:  A R Girbes; A J Smit; S Meijer; W D Reitsma
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

3.  Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Hypertension research program at ochsner: a program in translational research.

Authors:  Edward Frohlich
Journal:  Ochsner J       Date:  2002

5.  Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.

Authors:  W D Kerns; E Arena; D G Morgan
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

6.  A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites.

Authors:  J A Ziemniak; V K Boppana; M J Cyronak; R M Stote
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

7.  Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension.

Authors:  M P Caruana; M Heber; G Brigden; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

8.  A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

10.  Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

Authors:  R R Weber; C E McCoy; J A Ziemniak; E D Frederickson; L I Goldberg; M B Murphy
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.